• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by UroGen Pharma Ltd.

    11/6/25 4:29:03 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $URGN alert in real time by email
    S-8 1 d938113ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on November 6, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    UroGen Pharma Ltd.

    (Exact name of registrant as specified in its charter)

     

     

     

    State of Israel   98-1460746

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    400 Alexander Park Drive, 4th Floor

    Princeton, New Jersey

      08540
    (Address of Principal Executive Offices)   (Zip Code)

    2017 Equity Incentive Plan

    (Full titles of the plans)

    UroGen Pharma Ltd.

    Jason Smith

    General Counsel

    400 Alexander Park Drive, 4th Floor

    Princeton, New Jersey 08540

    Telephone: +1 (646) 768-9780

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Charles J. Bair

    Asa M. Henin

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    +1 (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    INCORPORATION BY REFERENCE

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plan are effective. The Registrant previously registered its Ordinary Shares for issuance under the Registrant’s 2017 Equity Incentive Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on June 27, 2017 (File No. 333-218992), February 9, 2018 (File No. 333-222955), October 12, 2018 (File No. 333-227812),  August 10, 2020 (File No. 333-243750),  August 5, 2021 (File No. 333-258496),  August 11, 2022 (File No. 333-266761), November  14, 2023 (File No. 333-275547) and August 13, 2024 (File No. 333-281520). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.


    ITEM 8. EXHIBITS.

     

    Exhibit

    Number

      

    Description

     4.1    Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Report on Form 6-K, furnished to the Securities and Exchange Commission on May 18, 2017).
     5.1    Opinion of Gornitzky & Co., Advocates, Israeli counsel to the Registrant, as to the validity of the Registrant’s Ordinary Shares.
    23.1    Consent of Independent Registered Public Accounting Firm.
    23.2    Consent of Gornitzky & Co., Advocates Reference is made to Exhibit 5.1.
    24.1    Powers of Attorney. Reference is made to the signature page hereto.
    99.1    UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on August 27, 2025).
    107    Filing Fee Table


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, State of New Jersey, on November 6, 2025.

     

    UROGEN PHARMA LTD.
    By:  

    /s/ Elizabeth Barrett

      Elizabeth Barrett
      President and Chief Executive Officer

    POWERS OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Elizabeth Barrett and Chris Degnan, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Elizabeth Barrett

      

    President, Chief Executive Officer and Director

      

    November 6, 2025

    Elizabeth Barrett   

    (Principal Executive Officer)

      

    /s/ Chris Degnan

      

    Chief Financial Officer

      

    November 6, 2025

    Chris Degnan   

    (Principal Financial and Accounting Officer)

      

    /s/ Arie Belldegrun

      

    Chair

      

    November 6, 2025

    Arie Belldegrun, M.D.      

    /s/ Cynthia Butitta

      

    Director

      

    November 6, 2025

    Cynthia Butitta      

    /s/ Leana S. Wen

      

    Director

      

    November 6, 2025

    Leana S. Wen, M.D., M.Sc.      

    /s/ Stuart Holden

      

    Director

      

    November 6, 2025

    Stuart Holden, M.D.      

    /s/ James Robinson Jr.

      

    Director

      

    November 6, 2025

    James Robinson Jr.      

    /s/ Daniel Wildman

      

    Director

      

    November 6, 2025

    Daniel Wildman      
    Get the next $URGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $URGN

    DatePrice TargetRatingAnalyst
    8/19/2025$36.00Overweight
    Piper Sandler
    6/16/2025$50.00Neutral → Buy
    H.C. Wainwright
    5/22/2025Buy → Neutral
    H.C. Wainwright
    4/16/2025$23.00Sector Outperform
    Scotiabank
    2/19/2025$31.00Buy
    Ladenburg Thalmann
    8/22/2024$40.00Buy
    Guggenheim
    2/8/2023$35.00 → $10.00Buy → Hold
    Jefferies
    4/27/2022$20.00Buy
    Berenberg
    More analyst ratings

    $URGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

    Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code (J9282) in October 2025, effective January 1, 2026ZUSDURI achieved net product revenue of $1.8 million in Q3 2025; October 2025 preliminary demand revenue estimate of $4.5 million reflecting accelerating growth entering Q4 2025JELMYTO® achieved net product revenue of $25.7 million in Q3 2025, representing YoY underlying demand revenue growth of 13% $127.4 million in cash, cash equivalents and marketable securities as of September 30, 2025 Conference cal

    11/6/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

    PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced robust preliminary results from its ongoing Phase 3 UTOPIA trial, demonstrating a 77.8% three-month complete response (CR) rate (95% CI, 68.3%, 85.5%) with UGN-103 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This result is consistent with the 79.6% three-month CR rate (95% CI, 73.9%, 84.5%) observed following treatment with ZUSDURI in the pivotal ENVISION trial. In ad

    11/6/25 7:58:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

    PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Guggenheim Securities Healthcare Innovation Conference to take place on November 10-12, 2025. Guggenheim Securities Innovation Conference Date / Time:November 11, 2025 at 10:30 AM ETFormat:Presentation and 1x1 investor meetingsLocation:Boston, MAWebcast Link:here   Webcasts from the conferences will also be available on UroGen's Investor Relations website. A replay will be available on the site for approximately 90 days. About UroGen P

    11/4/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on UroGen Pharma with a new price target

    Piper Sandler initiated coverage of UroGen Pharma with a rating of Overweight and set a new price target of $36.00

    8/19/25 8:36:26 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded UroGen Pharma from Neutral to Buy and set a new price target of $50.00

    6/16/25 7:44:13 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded UroGen Pharma from Buy to Neutral

    5/22/25 8:22:21 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Degnan Chris converted options into 4,483 units of Ordinary Shares and sold $37,121 worth of Ordinary Shares (2,203 units at $16.85) (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    10/9/25 1:37:33 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Schoenberg Mark converted options into 1,667 units of Ordinary Shares and sold $16,645 worth of Ordinary Shares (871 units at $19.11), increasing direct ownership by 0.54% to 149,025 units (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    9/9/25 6:37:09 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Smith Jason Drew sold $29,047 worth of Ordinary Shares (1,520 units at $19.11) and converted options into 3,333 units of Ordinary Shares, increasing direct ownership by 4% to 43,305 units (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    9/9/25 6:32:09 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.

    SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/18/24 6:16:04 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

    SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/14/24 7:46:37 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

    SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/14/24 5:46:12 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    SEC Filings

    View All

    SEC Form S-8 filed by UroGen Pharma Ltd.

    S-8 - UroGen Pharma Ltd. (0001668243) (Filer)

    11/6/25 4:29:03 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by UroGen Pharma Ltd.

    S-3ASR - UroGen Pharma Ltd. (0001668243) (Filer)

    11/6/25 4:22:38 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by UroGen Pharma Ltd.

    10-Q - UroGen Pharma Ltd. (0001668243) (Filer)

    11/6/25 8:02:08 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Leadership Updates

    Live Leadership Updates

    View All

    UroGen Appoints Chris Degnan as Chief Financial Officer

    Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-musc

    10/9/24 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma Appoints David Lin as New Chief Commercial Officer

    UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining U

    6/3/24 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStar Appoints Peter Pfreundschuh to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

    4/15/24 9:00:00 AM ET
    $FREQ
    $URGN
    $VYGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $URGN
    Financials

    Live finance-specific insights

    View All

    UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

    Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code (J9282) in October 2025, effective January 1, 2026ZUSDURI achieved net product revenue of $1.8 million in Q3 2025; October 2025 preliminary demand revenue estimate of $4.5 million reflecting accelerating growth entering Q4 2025JELMYTO® achieved net product revenue of $25.7 million in Q3 2025, representing YoY underlying demand revenue growth of 13% $127.4 million in cash, cash equivalents and marketable securities as of September 30, 2025 Conference cal

    11/6/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

    PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2025 financial results on Thursday, November 6th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma Ltd. UroG

    10/30/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

    ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)JELMYTO® achieved net product sales of $24.2 million in Q2 2025, compared with $21.8 million in Q2 2024, representing 11% year-over-year growth$161.6 million in cash, cash equivalents and marketable securities as of June 30, 2025 Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and spec

    8/7/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care